vasoactive-intestinal-peptide has been researched along with Uveitis--Anterior* in 1 studies
1 other study(ies) available for vasoactive-intestinal-peptide and Uveitis--Anterior
Article | Year |
---|---|
Vasoactive intestinal peptide (VIP) exacerbates endotoxin-induced uveitis (EIU) in mice.
We have previously shown that inhibition of the proinflammatory cytokine tumor necrosis factor- (TNF)-alpha exacerbates the inflammatory process of EIU. To further examine this paradoxic phenomenon, we investigated here the effect on EIU of VIP, a neuropeptide that inbibits TNF-alpha production.. VIP was injected concurrently with endotoxin at doses that induce EIU or lethality in mice. Severity of EIU was measured by counting infiltrating cells in eye sections, at 1 or 5 days post endotoxin injection. Survival of mice was monitored periodically, while serum levels of TNF-alpha, interleukin-(IL)-1beta and IL-10 were determined by caputure ELISA.. Treatment with VIP exacerbated EIU but provided partial protection from the lethal endotoxin effect. VIP treatment also reduced serum levels of TNF-alpha and IL-1beta, but increased levels of IL-10.. This study further established the paradoxical observation that EIU is exacerbated by lowering the levels of circulating pro-inflammatory cytokines, in particular TNF-alpha. Topics: Animals; Anterior Eye Segment; Endotoxemia; Endotoxins; Enzyme-Linked Immunosorbent Assay; Interleukin-1; Interleukin-10; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Staphylococcal Infections; Staphylococcus; Tumor Necrosis Factor-alpha; Uveitis, Anterior; Vasoactive Intestinal Peptide | 2000 |